Highlights of This Issue 3297

HIGHLIGHTS

Special Report

3299 | AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development
Samir N. Khleif, James H. Doroshow, and William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative 3349

CCR Translations

3319 | ADAM-17: A Target to Increase Chemotherapeutic Efficacy in Colorectal Cancer?
Adam M. Lee and Robert B. Diasio 3368

3322 | New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK
Giorgia Zadra, Carmen Priolo, Akash Patnaik, and Massimo Loda 3390

MOLECULAR PATHWAYS

3329 | Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Pratilas and David B. Solit 3399

3335 | The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment
Ivor Caro and Jennifer A. Low

HUMAN CANCER BIOLOGY

3340 | BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood
Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich C. Weier, Krzysztof P. Bielawski, and Burkhard Brandt

Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer
Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe

Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome
Göran Jönsson, Christian Busch, Stian Knappskog, Jürgen Geisler, Hrvoje Miletić, Markus Ringnér, Johan R. Lillegaard, Åke Borg, and Per Eystein Lønning

A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas
Dorine A. Bax, Alan Mackay, Suzanne E. Little, Diana Carvalho, Marta Viana-Pereira, Narinder Tamber, Anita E. Grigoradis, Alan Ashworth, Rui M. Reis, David W. Ellison, Saif Al Sarraj, Darren Hargrave, and Chris Jones

Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer
Joan N. Kyula, Sandra Van Schaeybroeck, Joanne Doherty, Catherine S. Fenning, Daniel B. Longley, and Patrick G. Johnston

The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo

Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy
Darya Alizadeh, Leying Zhang, Christine E. Brown, Omar Farrukh, Michael C. Jensen, and Behnams Badie
ABOUT THE COVER

High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into LoxP-conditional p53 (or pten);Ink4a/Arf;K-Rasv12;LucR mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue.